Leukoencephalopathy has also been reported in a patient treated with platinum-based chemotherapy.560–562 The TLR9 agonist IMO-2055 has also been known to cause diarrhea, nausea, hypomagnesemia, dehydration, and stomatitis.561 The combination of the TLR9 agonist SD-101 with Pembrolizumab can induce vomiting, constipation, and increased γ-glutamyltransferase. This evidence concerns the gene TLR9 and Leukoencephalopathy.